<DOC>
	<DOCNO>NCT02453711</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate safety efficacy once-daily semaglutide obese subject without diabetes mellitus .</brief_summary>
	<brief_title>Investigation Safety Efficacy Once-daily Semaglutide Obese Subjects Without Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Male female , age 18 year old time sign inform consent Body mass index ( BMI ) equal 30.0 kg/m^2 screen visit At least one unsuccessful weight loss attempt per investigator judgement A HbA1c ( glycosylated haemoglobin ) equal 6.5 % screening diagnose type 1 type 2 diabetes mellitus Treatment glucose lower agent ( ) within 90 day screen Screening calcitonin equal 50 ng/L ( pg/mL ) Personal family history medullary thyroid carcinoma multiple endocrine neoplasia syndrome type 2 History pancreatitis ( acute chronic ) Obesity induce endocrine disorder ( e.g . Cushing Syndrome ) Treatment medication within 90 day screen base investigator 's judgement may cause significant weight change Previous surgical treatment obesity ( liposuction and/or abdominoplasty perform 1 year screening allow ) History major depressive disorder within 2 year randomisation Any lifetime history suicidal attempt Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure require local regulation practice )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>